Fabio Arcidiacono, Radiation Oncologist at S.Maria Hospital, shared a post on X about a recent article he and his colleagues co-authored, published in IJROBP – The Red Journal:
“I’m excited and proud to share the update of the STARTNEWERA phase II trial! Now in press on IJROBP – The Red Journal the 5-y survival and safety of SAbR in unresectable LA-NSCLC unfit for concurrent RT-ChT:focus on patterns of local recurrence!
- 23 patients SAbR alone
- 20 patients sequential ChT – >SAbR
- 7 patients sequential ChT->SAbR – >IO
76% of primary tumor was central
100% primary tumor and/or nodal overlapped central OAR
SIB and personalised SIP were implemented
Median FU 72months
No G3 toxicity
Median thoracic nodal recurrence-FS not reached
5-y 65%
Median distant progression-FS not reached
5-y 60%
92% oligo-M recurrence to SAbR
Median PFS 13 months
5-y PFS 26%
Median OS 53 months
3-y OS 70%
5-y OS 46%
17 patients had in-field local recurrence
Median LR-FS was not reached
5-y LR-FS 64%
Strong predictors LR
- squamous cell carcinoma
- SAbR dose <40Gy
The long-term outcomes of the #STARTNEWERA non randomized phase II trial confirm
- efficacy
- safety
SAbR in LA-NSCLC
1trial to investigate SAbR IO combination
SIB and SIP could explain low toxicity and can allow us to safely in the “no-fly” zone “to go”under 40 Gy
Thanks IJROBP – The Red Journal
Editorial Team,Editor in Chief Sue Yom for continuing believe in our trial giving us great opportunity to publish it in IJROBP – The Red Journal.
We are honored! Other great step for SAbR LA-NSCLC. Thanks patients and families.”
Title: 5-year survival and safety of stereotactic ablative radiotherapy in unresectable locally advanced non-small cell lung cancer patients unfit for concurrent radio-chemotherapy:focus on patterns of local recurrence from the START-NEW-ERA non-randomized phase II trial
Authors: Fabio Arcidiacono, Paola Anselmo, Michelina Casale, Cristina Zannori, Fabio Loreti, Benedetta Enrico, Valentina Tassi, Alessandro Di Marzo, Marco Italiani, Gustavo Arruda Viani, Ernesto Maranzano, Fabio Trippa
Read the Full Article on IJROBP – The Red Journal
More posts featuring Fabio Arcidiacono.
